Branches of biology

WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England

Friday, September 18, 2020 - 8:00am

This important milestone will allow patients with this severely debilitating condition to access treatment on the NHS, drastically improving their quality of life.

Key Points: 
  • This important milestone will allow patients with this severely debilitating condition to access treatment on the NHS, drastically improving their quality of life.
  • Akcea Therapeutics initially made volanesorsen available to patients with FCS through the Early Access to Medicines Scheme (EAMS).
  • Since initiation of the EAMS, 22 patients with FCS have been treated with volanesorsen, at no cost to the NHS.
  • Volanesorsen will be the second treatment that Akcea Therapeutics has made available through the NHS in the last year.

Vitamin C Supplements Market and Competitive Landscape & Pandemic Recovery Analysis 2020 - Technavio

Thursday, September 17, 2020 - 11:30pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200917005758/en/
    Technavio has announced its latest market research report titled Global Vitamin C Supplements Market 2020-2024 (Graphic: Business Wire)
    The research is classified into seven sections vitamin C supplements market landscape, market sizing, five force analysis, customer landscape, geographic landscape, drivers, challenges, and trends, and vendor landscape and analysis.
  • Vitamin C Supplements Region Growth: Find out the highest and slowest growth of regions for vitamin C supplements market.
  • Vitamin C Supplements Market Valuations: Find out the global market size for vitamin C supplements in 2019 and how the market will advance from 2020 to 2024.
  • Vitamin C Supplements Market Share: Find out the global market shares for key vitamin C supplements distribution channels.

Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020

Thursday, September 17, 2020 - 9:30pm

NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Virtual Summit 2020.

Key Points: 
  • NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Virtual Summit 2020.
  • Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients.
  • PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.
  • The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200.

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thursday, September 17, 2020 - 9:30pm

Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
  • The stock option was granted on September 16, 2020 at an exercise price of $1.81 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The option was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of a stock option agreement covering the grant and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

Thursday, September 17, 2020 - 9:05pm

The move rounds out QIAGENs portfolio of automated molecular testing solutions based on the proven PCR technology.

Key Points: 
  • The move rounds out QIAGENs portfolio of automated molecular testing solutions based on the proven PCR technology.
  • The transaction was completed after QIAGEN received U.S. regulatory clearance for the full acquisition.
  • In 2018, QIAGEN had purchased a 19.9% stake in NeuMoDx along with the right to acquire the remaining NeuMoDx stake at a price of $234 million.
  • The full integration of the NeuMoDx systems will allow QIAGEN to address laboratory needs in almost any setting for molecular diagnostics.

Link Between Low Vitamin D Levels and COVID-19 Researched By Ferris PolyMem's Dr. Linda Benskin

Thursday, September 17, 2020 - 7:02pm

Corp., the maker of PolyMem wound dressings, is pleased to announce the publication of "A Basic Review of the Preliminary Evidence that Covid-19 Risk and Severity is Increased in Vitamin D Deficiency" by longtime Ferris employee Linda Benskin, Ph.D.

Key Points: 
  • Corp., the maker of PolyMem wound dressings, is pleased to announce the publication of "A Basic Review of the Preliminary Evidence that Covid-19 Risk and Severity is Increased in Vitamin D Deficiency" by longtime Ferris employee Linda Benskin, Ph.D.
  • The extensive review article examines the relationship between low vitamin D levels and an individual's vulnerabilities to Covid-19.
  • Dr. Benskin's review found 188 reports addressing the hypothesis that vitamin D deficiency is related to the incidence and severity of Covid-19.
  • Dr. Benskin concluded that a clear common thread among the top risk groups vitamin D deficiency may be being overlooked because of previous overstated claims of vitamin D benefits.

'Know Your Potential' with Knosis - Cognizin® Citicoline Featured in New Nootropic + Energy Blend

Thursday, September 17, 2020 - 7:00pm

That's why Kyowa Hakko's Cognizin Citicoline ingredient is so critical to the efficacy and uniqueness of our product."

Key Points: 
  • That's why Kyowa Hakko's Cognizin Citicoline ingredient is so critical to the efficacy and uniqueness of our product."
  • Cognizin Citicoline is a patented, branded form of citicoline that is made by leading international health ingredient manufacturer, Kyowa Hakko, through a fermentation process.
  • Citicoline is a potent brain-health nutrient and nootropic that is especially vital to brain health and the formation of phospholipids.
  • A proprietary form of citicoline, Cognizin has been clinically studied to support mental energy, focus, attention, and recall.

Magnolia Medical Appoints Former Becton Dickinson Senior Executives to Its Medical & Scientific Advisory Board

Thursday, September 17, 2020 - 6:15pm

The MSAB board will continue to focus on Magnolia's new advanced products and integrated diagnostic technologies to reduce blood culture contamination and improve sepsis testing accuracy.

Key Points: 
  • The MSAB board will continue to focus on Magnolia's new advanced products and integrated diagnostic technologies to reduce blood culture contamination and improve sepsis testing accuracy.
  • The Diagnostic Systems business unit comprised several BD Market Segment Areas including Molecular Diagnostics, Women's Health and Cancer, Microbiology, and Point of Care Diagnostics.
  • I look forward to contributing to Magnolia's Medical & Scientific Advisory Board to guide development of innovative solutions for sepsis management."
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.

ViaClean Technologies Offers To Safeguard American Icons By Donating Revolutionary BIOPROTECTUs™ System

Thursday, September 17, 2020 - 6:13pm

The announcement was made this week by Greg Tipsord, President and Chief Executive Officer of ViaClean Technologies.

Key Points: 
  • The announcement was made this week by Greg Tipsord, President and Chief Executive Officer of ViaClean Technologies.
  • To support the nation's reopening of the country, ViaClean Technologies is in discussion with some of America's most beloved landmarks to donate its revolutionary BIOPROTECTUsSystem.
  • As part of this promise, ViaClean will reapply the BIOPROTECTUsSystem every 90 days in order to continuously safeguard.
  • ViaClean Technologies' pioneering and proprietary technologies, products and services provide antibacterial, antimicrobial, disinfectant and advanced odor control solutions for commercial, institutional and consumer use.

Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecasts to 2025 - Cumulative Impact of COVID-19 - ResearchAndMarkets.com

Thursday, September 17, 2020 - 4:14pm

This research report categorizes the Viral Vector & Plasmid DNA Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Viral Vector & Plasmid DNA Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:
    On the basis of Type, the Viral Vector & Plasmid DNA Manufacturing Market is examined across Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA.
  • On the basis of End User, the Viral Vector & Plasmid DNA Manufacturing Market is examined across Biotech Companies and Research Institutes.
  • What are the technology trends and regulatory frameworks in the Global Viral Vector & Plasmid DNA Manufacturing Market?
  • What are the modes and strategic moves considered suitable for entering the Global Viral Vector & Plasmid DNA Manufacturing Market?